# Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

> **NCT01904682** · PHASE2 · COMPLETED · sponsor: **Traws Pharma, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Oral rigosertib

## Key facts

- **NCT ID:** NCT01904682
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2020-12
- **Final completion:** 2021-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01904682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01904682, "Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01904682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*